SCHEMBL12092174

SCHEMBL12092174

COC(=O)CCOCCOS(C)(=O)=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.44
CA12 O43570 6/20 0.42
CA14 Q9ULX7 6/20 0.42
LMNA P02545 4/20 0.41
ALDH1A1 P00352 3/20 0.41
KDM4E B2RXH2 2/20 0.41
USP2 O75604 2/20 0.41
MMP9 P14780 1/20 0.41
ALOX15 P16050 1/20 0.41
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
CA7 P43166 4/20 0.35
CA9 Q16790 4/20 0.35
CA2 P00918 2/20 0.34
FNTA P49354 1/20 0.34
FNTB P49356 1/20 0.34
HSD17B10 Q99714 2/20 0.33
MAPT P10636 1/20 0.33
HTT P42858 1/20 0.33
MGAM O43451 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5265771 0.88 TSHR (0.52) TSHRCA12CA14LMNAALDH1A1
SCHEMBL3682553 0.83 TSHR (0.63) TSHRCA12CA14LMNAALDH1A1
SCHEMBL12092176 0.82 TSHR (0.43) TSHRCA12CA14LMNAALDH1A1
SCHEMBL27225836 0.82 TSHR (0.50) TSHRCA12CA14LMNAALDH1A1
SCHEMBL18106039 0.81 CYP1A2 (0.40) TSHRLMNAALDH1A1KDM4EUSP2
SCHEMBL4060095 0.81 TSHR (0.67) TSHRCA12CA14LMNAALDH1A1
SCHEMBL12092173 0.80 KDM4E (0.38) TSHRCA12CA14LMNAALDH1A1
SCHEMBL13008106 0.80 KDM4E (0.38) TSHRCA12CA14LMNAALDH1A1
SCHEMBL19285817 0.80 KDM4E (0.38) TSHRCA12CA14LMNAALDH1A1
SCHEMBL2048408 0.80 KDM4E (0.38) TSHRCA12CA14LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952147-B2 Conjugates, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-02-10 US disclosed
US-8952147-B2 Conjugates, preparation thereof, and therapeutic use thereof SANOFI (FR) 2015-02-10 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-09-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225089-A1 NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF ERG28, CARS1, FOLH1 TSHR 4077/4885CA12 280/4885CA14 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.